5 Key Takeaways

• 1

  The INSTANT trial found that tirofiban improved functional outcomes at 90 days in stroke patients with inadequate response to tenecteplase.

• 2

  In the trial, 64% of patients receiving tirofiban achieved an excellent outcome, compared to 52% receiving placebo.

• 3

  The trial included 359 patients with acute ischemic stroke and excluded those with large-vessel occlusion or cardioembolic sources.

• 4

  Tirofiban was administered after tenecteplase, with a number needed to treat of 8.7 for achieving excellent outcomes.

• 5

  The study's findings may not apply to patients with minor strokes or those treated outside the early thrombolysis window.